Vol. 8, Issue 3, Part A (2021)

Author(s): Seema Garg and Shashi Meena

Abstract: The Corona pandemic, brought about by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is pronounced international public health crisis with shocking health impacts. The Covid-19 disease has created the symptoms misdiagnosis complicacy in tropical and subtropical areas of the world, that are dengue endemic regions too to the population. The dengue is cause by dengue virus (DENV). Initially, there is similarity in the sign and symptoms of patients with Covid-19 and dengue, namely fever, headache, myalgia associated with thrombocytopenia, leukopenia, and abnormal liver function tests. The similarity in clinical symptoms in Covid-19 and dengue fever has to raise the issue of co-infection and symptoms misleading. In addition, co-infection followed by cross-reactivity between antibodies against DENV and SARS-CoV-2 serology tests has been recorded in reports. Furthermore, cross-reactivity of the immune reaction in these infections is an emerging issue, Covid-19 through counteracting agent subordinate upgrade as pre-existing DENV-antibodies may possibly influence Covid-19 through antibody-dependent enhancement. Some studies have proposed that Covid-19 disease and transmission might be slower in dengue-endemic locales of the world. This review deals with the concern of misdiagnosis challenges due to Covid-19 and dengue fever, co-infection, cross-reactivity between SARS-CoV-2 and DENV antibodies. Simultaneous pandemics of dengue and Covid-19, just as the chance of co-contamination, add to the generally significant burden on healthcare services.

DOI: 10.22271/23487941.2021.v8.i3a.539